ADR Therapeutics Commences Joint Research with Medical Arc on Canine Joint and Inflammatory Diseases Using 'Neocella'

ADR Therapeutics, a subsidiary of ADR120S (TSE Standard: 3750, President: Michimichi Hashimoto), has commenced research on the application of its next-generation extracellular particle product 'Neocella' for companion animals (dogs), based on a joint research agreement concluded with Medical Arc (President: Hiroshi Ito), effective May 21, 2026.

Background: Increasing Demand for Regenerative Medicine in Companion Animals

In recent years, the aging trend in companion animals has accelerated, leading to a rapidly increasing demand for 'regenerative medicine' to address chronic inflammation, joint diseases, and gait disorders. Domestically and internationally, various research initiatives are underway to address these challenges.

Overview and Purpose of the Joint Research

This joint research project will be spearheaded by Dr. Hiroshi Ito, President of Medical Arc and Professor Emeritus at Tokyo University of Agriculture and Technology. The study will explore the potential of 'Neocella' in ameliorating conditions and suppressing inflammation in dogs suffering from inflammatory diseases, joint diseases, and other age-related pathologies. Researchers will use 'Neocella' in actual clinical treatments, accumulate case records and post-treatment follow-up data, and conduct veterinary analysis and evaluation.

Key Considerations of the Joint Research:

- Observational research on inflammatory conditions in the small animal (dog) field - Examination of potential applications for joint diseases and gait disorders - Evaluation of the utility of cell-derived components in the small animal field - Accumulation of case data and veterinary analysis - Collection of foundational data for the overseas licensing of Neocella

Multifaceted Approach Toward Early Commercialization

ADR Therapeutics is pursuing joint research through multifaceted approaches, not limited to this project, aiming for the early commercialization of 'Neocella.'

With the commencement of this research targeting companion animals (dogs), the company aims to further expand the potential applications of 'Neocella' to the small animal field and create new veterinary value.

Future Outlook

The impact of the commencement of this joint research on the company's financial results is considered minor at this stage. The company will promptly announce any matters that need to be disclosed in the future.